title: Human telomerase and alpha-methylacyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study.
abstract: Human telomerase detected by in situ hybridization has been demonstrated to be a useful tool for the diagnosis of malignancy and has also been tested by reverse transcriptase-polymerase chain reaction in several tumors such as hepatic cell carcinoma, melanoma, colonic carcinoma, gastric carcinoma, biliary carcinoma, breast carcinoma, mesothelioma, lung carcinoma, female tract carcinoma, and prostatic carcinoma. A monoclonal antibody (clone Tel-24) that allows for the detection of human telomerase reverse transcriptase (hTERT) in paraffin blocks of archival material has recently been developed. Carcinomas of cervix, endometrium, and breast have been studied by this method, but its value in prostatic carcinoma has not been explored; for that reason, we studied benign and malignant prostatic lesions by immunohistochemistry using paraffin embedded tissue. The aim of the study was to define the sensitivity and specificity of hTERT in prostate cancer, in comparison with alpha-methylacyl-coenzyme A racemase (AMACR) (P504-S). Fifty-five specimens of diverse prostatic lesions were selected for study (43 needle biopsies and 12 transurethral resections); there were 61 malignancies (47 infiltrating carcinomas and 14 high-grade prostatic intraepithelial neoplasias [PIN]) and 29 benign lesions (10 basal cell hyperplasias, 12 nodular hyperplasias, 4 chronic prostatitis, and 3 atrophic glands). Signal for hTERT nucleolar was detected in 31 of 47 infiltrating adenocarcinomas, in 11 of 14 PIN, and in none of 27 benign lesions (sensitivity, 71%; specificity, 100%). Diffuse cytoplasmic positivity for AMACR was found in 37 of 41 infiltrating adenocarcinomas, in 7 of 7 PIN, and in 6 of 22 benign lesions (sensitivity, 91%; specificity, 72%). These results indicate that hTERT is highly specific of malignancy, with no false-positive cases; however, it had lower sensitivity than AMACR.
authors.affiliation: Department of Pathology, Instituto Nacional de Cancerologia, Tlalpan, D.F. 14080, México.
authors.forename: Ana Graciela
authors.initials: AG
authors.lastname: Puebla-Mora
authors.forename: Alfonso
authors.initials: A
authors.lastname: Heras
authors.forename: Ana María
authors.initials: AM
authors.lastname: Cano-Valdez
authors.forename: Hugo
authors.initials: H
authors.lastname: Domínguez-Malagón
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology* / Q000473:pathology / Q000601:surgery; D001706:Biopsy; D004268:DNA-Binding Proteins / Q000378:metabolism*; D006801:Humans; D007124:Immunoenzyme Techniques / Q000379:methods*; D008297:Male; D019048:Prostatic Intraepithelial Neoplasia / Q000201:enzymology* / Q000473:pathology / Q000601:surgery; D011471:Prostatic Neoplasms / Q000201:enzymology* / Q000473:pathology / Q000601:surgery; D019998:Racemases and Epimerases / Q000378:metabolism*; D012680:Sensitivity and Specificity; D019098:Telomerase / Q000378:metabolism*
chemical_list: D004268:DNA-Binding Proteins; D019098:Telomerase; D019998:Racemases and Epimerases; C108352:alpha-methylacyl-CoA racemase